AngioDynamics Raises FY2026 Adj EPS Guidance from $(0.33)-$(0.23) to $(0.30)-$(0.23) vs $(0.29) Est; Raises FY2026 Sales Guidance from $312.000M-$314.000M to $313.500M-$315.500M vs $312.881M Est

AngioDynamics has updated its fiscal year 2026 adjusted EPS guidance, raising it from a range of $(0.33)-$(0.23) to $(0.30)-$(0.23), compared to an analyst estimate of $(0.29). Additionally, the company increased its sales outlook for FY2026 from $312.000 million-$314.000 million to $313.500 million-$315.500 million, surpassing the previous estimate of $312.881 million.